Department of Obstetrics and Gynecology, AOUI Verona, University of Verona, Verona, Italy.
Department of Obstetrics and Gynecology, "Sacro Cuore" Hospital, Negrar Di Valpolicella, Verona, Italy.
Arch Gynecol Obstet. 2021 Jan;303(1):259-268. doi: 10.1007/s00404-020-05749-2. Epub 2020 Aug 27.
To compare fertility and reproductive outcome after surgical, medical, and expectant management for tubal ectopic pregnancy (EP).
133 of 228 patients, who were managed between January 2012 and December 2017 for a tubal EP, tried to conceive immediately after treatment: 86 out of 173 (49.7%) underwent surgical treatment; 38 (21.9%) were treated with methotrexate (MTX), and 49 (28.3%) had expectant management. Clinical data were retrieved by medical records, fertility outcomes were obtained by phone follow-up. The cumulative incidence (CI) of intrauterine clinical pregnancy (CP), miscarriage, live birth (LB), and recurrent EP, and the time between treatment and first intrauterine CP were compared between women treated with MTX, surgery and expectant management.
The CI of intrauterine CP starting from 12 months after the EP was 65.3% for the expectant management, 55.3% for the MTX group, and 39.5% for surgery (p = 0.012). Post-hoc analysis showed expectant management having higher intrauterine CP and LB, and shorter time between treatment and first intrauterine CP compared to surgery (p < 0.05). The CI of recurrent EP was comparable between the 3 groups. The analysis stratified per βhCG cut-off of 1745 mUI/mL and EP mass cut-off of 25 mm reported consistent results.
Women successfully managed by expectation appear to have better reproductive outcomes compared to women who underwent surgery, with the shortest time to achieve a subsequent intrauterine CP. Therefore, if safely applicable the expectant management should be considered in the case of tubal EP. The fact that the chosen treatment was primarily guided by the βhCG value and EP mass diameter based on the protocol, which is intrinsically related to the characteristics of the EP, represents the main limitation of the present study. Indeed, we cannot completely exclude that the observed differences between treatments are related to the EP itself instead of the treatment.
比较输卵管异位妊娠(EP)患者接受手术、药物和期待治疗后的生育和生殖结局。
2012 年 1 月至 2017 年 12 月期间,对 228 例输卵管 EP 患者进行了治疗,其中 133 例患者在治疗后立即尝试受孕:173 例患者中 86 例(49.7%)接受了手术治疗;38 例(21.9%)接受了甲氨蝶呤(MTX)治疗,49 例(28.3%)接受了期待治疗。通过病历检索临床数据,通过电话随访获得生育结局。比较 MTX 治疗、手术治疗和期待治疗后患者的宫内临床妊娠(CP)、流产、活产(LB)和复发性 EP 的累积发生率(CI),以及治疗后首次宫内 CP 的时间。
从 EP 后 12 个月开始,期待治疗的宫内 CP 累积发生率为 65.3%,MTX 组为 55.3%,手术组为 39.5%(p=0.012)。事后分析显示,期待治疗的宫内 CP 和 LB 更高,且治疗后首次宫内 CP 的时间更短(p<0.05)。3 组复发性 EP 的 CI 无差异。根据 1745mIU/ml 的βhCG 截断值和 25mm 的 EP 肿块截断值进行分层分析,报告了一致的结果。
与手术治疗相比,成功接受期待治疗的患者似乎具有更好的生殖结局,且实现随后宫内 CP 的时间最短。因此,如果可以安全应用,那么期待治疗应考虑用于输卵管 EP 患者。目前研究的主要局限性在于,所选治疗方法主要根据方案中的βhCG 值和 EP 肿块直径指导,这与 EP 的特征密切相关。实际上,我们不能完全排除观察到的治疗方法之间的差异与 EP 本身而不是治疗有关。